Breakthrough findings in the clinical and preclinical development of tuberculosis (TB)
vaccines have galvanized the field and suggest, for the first time since the development of …

Tuberculosis (TB), caused by Mycobacterium tuberculosis is the world's deadliest bacterial
infection, resulting in more than 1.4 million deaths annually. The emergence of drug …

Efficient and targeted delivery of a DNA payload is vital for develo** safe gene therapy.
Owing to the recent success of commercial oncolytic vector and multiple COVID-19 …

Tuberculosis (TB), caused by respiratory infection with Mycobacterium tuberculosis, remains
a major global health threat. The only licensed TB vaccine, the one-hundred-year-old Bacille …

Viral-vectored vaccines are highly amenable for respiratory mucosal delivery as a means of
inducing much-needed mucosal immunity at the point of pathogen entry. Unfortunately …

Chemotherapeutic intervention remains the primary strategy in treating and controlling
tuberculosis (TB). However, a complex interplay between therapeutic and patient-related …

Vaccination route dictates the quality and localization of immune responses within tissues.
Intranasal vaccination seeds tissue-resident adaptive immunity, alongside trained innate …

Tuberculosis (TB) is a major global health threat that claims more than one million lives
annually. With a quarter of the global population harbouring latent TB, post-exposure …

Tuberculosis (TB) is an ancient global public health problem. Several strategies have been
applied to develop new and more effective vaccines against TB, from attenuated or …

As components of the innate immune response, antimicrobial peptides (AMPs) efficiently
contribute to infection control and maintenance of a latent state in pulmonary tuberculosis …